{"name":"Stephen Chan Lam","slug":"stephen-chan-lam","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Lenvatinib and Sorafenib","genericName":"Lenvatinib and Sorafenib","slug":"lenvatinib-and-sorafenib","indication":"RCC (Renal Cell Carcinoma)","status":"phase_2"}]}],"pipeline":[{"name":"Lenvatinib and Sorafenib","genericName":"Lenvatinib and Sorafenib","slug":"lenvatinib-and-sorafenib","phase":"phase_2","mechanism":"Multi-kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), fibroblast growth factor receptors (FGFR), and other kinases.","indications":["RCC (Renal Cell Carcinoma)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxOc3kzVHJYXzU1S0hjRmZwcnNpQ0xHXzVqLXRWTG9XRkJIZkRERU1ua05SSVVHaUpVQnNfVm5TRGZ4SkhUS00wa1I2S0k2Nko5MWFPTkpLM2tFV0xxbGhNdUFCVExkZU1lOGdXc2syaE9kQkstN0tyOHhBSXBzYlhMTGtvdXpHWXgyUGhndVJUekRIUlk1V0RZY2Y1UVBkZGZHNmlFcm1uNWN3MDdXcGNtb2g2X2J4a2JhR0s4Z21EZG1mTW45azRUNW96eGZLalk2ODhwZnVhRnFRTUU?oc=5","date":"2025-08-27","type":"pipeline","source":"The Chinese University of Hong Kong","summary":"CUHK and mainland scholars formed the first Chinese-led The Lancet Commission on cancer Liver cancer cases are projected to double by 2050, but 60% are preventable - The Chinese University of Hong Kon","headline":"CUHK and mainland scholars formed the first Chinese-led The Lancet Commission on cancer Liver cancer cases are projected","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxNbG9ZellMSVRLNjJZYVVrejU4Nk1HNjlwT1NkUUd5bktjQzdkT0s1Y0FiTktqaHZsbnM0SzJkSHV5UXhzMDgwcU5TR2ZMZklOdlNlQzNYckFZLXQ1NmR4ZklTX2hQaUFwa18zQXcyal9uWTZyVjE1QnlJUHV5UV9paC0xSUZGV3I5OU9wSnBIVXcxbDZUODBqZnFwdnFaMlZucTlEMXg2bGFmYlN4WVZUUFNiZEN1MjBEZV9SbmhFWm5hQ0ZPeTFmOFR5cnotanJtSGNsTVZDeG8zWllvR1M4bGh3?oc=5","date":"2025-08-27","type":"pipeline","source":"thestandard.com.hk","summary":"Cutting alcohol and managing obesity could prevent 60pc of liver cancer cases, CUHK research finds - thestandard.com.hk","headline":"Cutting alcohol and managing obesity could prevent 60pc of liver cancer cases, CUHK research finds","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNcDl1bFoxNDVOb21aSVk3SUNyUDhVdzVWT3RKOHZJQjBaYjZYaDJ3RUpES19DOEhvX052VEZKeUZSclI0Wks5RmNLZkIxb2RXV0lEeEpPZF8xWVpOdk44dkd4NURzdkVtUmdDa1VnSWUxSHo4b1o0ZE9jV0plNkctbG1fQzBoUm94UEVZ?oc=5","date":"2025-07-28","type":"pipeline","source":"The Lancet","summary":"The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment - The Lancet","headline":"The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5RVmJQRGo4TzctLTBKdG9SM0RBd01mdU93QVVSRTFWbExtblNZMVlxZXRZcEd0X2p6SkNMYUhETkYtNGM3dEt3eWdWeEJqTUU5aFpfNVJVck9kblE0OUdV?oc=5","date":"2024-07-05","type":"pipeline","source":"nature.com","summary":"Effectiveness and safety of continuous low-molecular-weight heparin versus switching to direct oral anticoagulants in cancer-associated venous thrombosis - nature.com","headline":"Effectiveness and safety of continuous low-molecular-weight heparin versus switching to direct oral anticoagulants in ca","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxOVXQ1cVFuV2dKWDZNaXJmb3BRdC1tMGRWTzlxQ1FDMzRjSGRVWW5ZR0d2NGR4dDZFSHFlTVBKVV9Ubnc4ZWppcXNzeGpydXFLdUwxcGNXVTNNSzh4d21CNTh6b055T0RTaVUxcVpxaGFxM1VDeGRGRHMwM042M3VCOWUzaG9EZU1xeXFuNmdpbTJMbi1FR0VZdEZXdjM2R1Y3TGcyVWVFTURzeEsybFNFZHdGRC1tVGNQeG1RT1hsMmFhQ2t5WmFUX3c2X1ZFTENoNE9zUDNjZmNoQ0JVSTA3OFh2cVI1NGo1RlVPalNwRE5icEVQc1NYdk1yZldDa19TMzRHdnlB?oc=5","date":"2022-08-08","type":"trial","source":"The Chinese University of Hong Kong","summary":"CUHK leading Asia’s battle to improve bile duct cancer survival rates by developing a novel combinational strategy in clinical trial - The Chinese University of Hong Kong","headline":"CUHK leading Asia’s battle to improve bile duct cancer survival rates by developing a novel combinational strategy in cl","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":0,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}